Current trials in erythropoietic protoporphyria: are placebo controls ethical?
OPEN ACCESS
Loading...
Author / Producer
Date
2023
Publication Type
Journal Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
A new active substance called “dersimelagon” (MT-7117) is being tested as an alternative treatment option for Erythropoietic protoporphyria (EPP). At the moment, dersimelagon is being tested both in the US and in Europe in a phase III placebo-controlled RCT. However, given the availability of an already approved treatment option for EPP the use of a placebo arm is questionable from an ethics point of view. We analyze the issue and suggest that a noninferiority active-control trial without placebo is an ethically and scientifically more valid design to test the efficacy of dersimelagon as well as other EPP treatments.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
18 (1)
Pages / Article No.
325
Publisher
BioMed Central
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Organisational unit
09614 - Vayena, Eftychia / Vayena, Eftychia